Vaginal Delivery without Sterilization or D&C with MCC DRG Reimbursement

DRG 805 encompasses vaginal deliveries without sterilization or dilation and curettage that are complicated by a Major Complication or Comorbidity, increasing resource use during the inpatient stay. Proper documentation and coding of the qualifying Major Complication or Comorbidity affect Diagnosis-Related Group assignment and therefore influence inpatient reimbursement under Medicare.

DRG 805 Overview

DRG 805 covers inpatient stays for vaginal delivery without sterilization or dilation and curettage when a Major Complication or Comorbidity is present, typically involving significant maternal conditions that increase resource use. This Diagnosis-Related Group is used by the Centers for Medicare & Medicaid Services to classify and reimburse hospital admissions for childbirth when additional serious diagnoses are coded. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates the relative weight and thus the prospective payment for the admission. Accurate clinical documentation and coding of the qualifying Major Complication or Comorbidity determine assignment to this Diagnosis-Related Group.

Peripartum hemorrhage prevention and management trials: randomized or pragmatic studies testing protocols, timing, and combinations of uterotonic agents, tranexamic acid administration, and active management of the third stage of labor among patients undergoing vaginal delivery complicated by major comorbidities (eg, placenta accreta spectrum suspicion, severe anemia, hypertensive disorders). The patient population includes term or near-term pregnant individuals delivering vaginally who develop or are at high risk for significant postpartum hemorrhage (an MCC), and studies assess metrics such as blood loss quantification, need for transfusion, emergency surgical interventions, and length of stay. This research is relevant to providers and payers because effective hemorrhage prevention and rapid treatment reduce maternal morbidity, resource utilization (blood products, operating room time), and downstream costs associated with complications coded as MCCs under this DRG.
Comparative effectiveness studies of labor management strategies in high-risk vaginal deliveries: prospective cohort or randomized trials comparing approaches such as induction versus expectant management, epidural analgesia timing, or specific intrapartum monitoring protocols for patients with significant maternal comorbidities (eg, preeclampsia with severe features, cardiac disease, or severe obesity). These studies enroll pregnant patients for whom vaginal delivery remains the intended mode but who carry major complications that influence intrapartum decision-making, and they measure outcomes including mode of delivery, maternal intensive care unit admissions, neonatal complications, and cost per admission. Findings inform clinicians and payers about which labor management pathways optimize maternal and neonatal outcomes while minimizing escalation to higher-cost DRGs or extended hospitalization.
Postpartum functional recovery and readmission prevention studies: observational and interventional studies examining post-discharge care bundles, early postpartum follow-up, mental health screening, and transitional care coordination for patients discharged after a vaginal delivery complicated by major comorbid conditions (eg, severe hypertensive disorders, significant perineal trauma, or infection). The population includes patients with MCC during delivery who are at higher risk for readmission, wound complications, or delayed recovery; endpoints include 30-day readmission rates, postpartum complications, patient-reported recovery and breastfeeding success, and total post-discharge cost of care. This area is important to providers and payers because reducing readmissions and improving recovery trajectories can lower overall episode costs and improve quality metrics associated with this DRG.

Peripartum hemorrhage prevention and management trials: randomized or pragmatic studies testing protocols, timing, and combinations of uterotonic agents, tranexamic acid administration, and active management of the third stage of labor among patients undergoing vaginal delivery complicated by major comorbidities (eg, placenta accreta spectrum suspicion, severe anemia, hypertensive disorders). The patient population includes term or near-term pregnant individuals delivering vaginally who develop or are at high risk for significant postpartum hemorrhage (an MCC), and studies assess metrics such as blood loss quantification, need for transfusion, emergency surgical interventions, and length of stay. This research is relevant to providers and payers because effective hemorrhage prevention and rapid treatment reduce maternal morbidity, resource utilization (blood products, operating room time), and downstream costs associated with complications coded as MCCs under this DRG.
Comparative effectiveness studies of labor management strategies in high-risk vaginal deliveries: prospective cohort or randomized trials comparing approaches such as induction versus expectant management, epidural analgesia timing, or specific intrapartum monitoring protocols for patients with significant maternal comorbidities (eg, preeclampsia with severe features, cardiac disease, or severe obesity). These studies enroll pregnant patients for whom vaginal delivery remains the intended mode but who carry major complications that influence intrapartum decision-making, and they measure outcomes including mode of delivery, maternal intensive care unit admissions, neonatal complications, and cost per admission. Findings inform clinicians and payers about which labor management pathways optimize maternal and neonatal outcomes while minimizing escalation to higher-cost DRGs or extended hospitalization.
Postpartum functional recovery and readmission prevention studies: observational and interventional studies examining post-discharge care bundles, early postpartum follow-up, mental health screening, and transitional care coordination for patients discharged after a vaginal delivery complicated by major comorbid conditions (eg, severe hypertensive disorders, significant perineal trauma, or infection). The population includes patients with MCC during delivery who are at higher risk for readmission, wound complications, or delayed recovery; endpoints include 30-day readmission rates, postpartum complications, patient-reported recovery and breastfeeding success, and total post-discharge cost of care. This area is important to providers and payers because reducing readmissions and improving recovery trajectories can lower overall episode costs and improve quality metrics associated with this DRG.

OpenPayer

Summary & Overview

Vaginal Delivery without Sterilization or D&C with MCC: Inpatient Reimbursement Overview

DRG 805 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes